Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out
March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, April 27, 2009

could PTC124 help with primary trimethylaminuria due to a nonsense mutation ?

As mentioned in the post about the Australian trimethylaminuria research proposal, one of the two proposed experimental treatments for trimethylaminuria is using the drug PTC124 (to be marketed as Ataluren), in cases where the person has primary trimethylaminuria due to a nonsense mutation of the FMO3 enzyme. Nonsense mutations instruct the developing protein (in this case FMO3 protein) to prematurely stop, and in effect abort the development. Nonsense mutations are also known as 'stop codons'. PCT124 (along with some antibiotics which have already been shown to have the same effect, but have side effects) has been claimed to overrule If it was of benefit, it would only be expected to work in a trimethylaminuria sufferer who had primary trimethylaminuria due to a nonsense mutationany nonsense mutation premature stop, and so allow whatever protein that was developing (in trimethylaminuria ; FMO3 enzyme) to fully develop. It must be presumed they expect more protein to develop only to a certain degree (i.e. they don't expect function to become 100%, but perhaps increase the level by 5% or more).

At the moment PTC124 is not available, except for research purposes (so if anyone knew any trimethylaminuria experts, they would be able to use it in research). It is being used in trials for muscular dystrophy and soon in cystic fibrosis. It seems it could get FDA approval in 2010 or shortly thereafter, assuming all goes well in the final trials. In mice and in a small group of human trialists, there seems to be no side effects except apart from upset stomach in a few. The toxicology data looks very promising. It is taken orally as a powder, for instance in water or fruit juice. If it was of benefit, it would only be expected to work in a trimethylaminuria sufferer who had primary trimethylaminuria due to a nonsense mutation. Offhand, it's not known how many have this type of mutation in FMO3. In some other illnesses (it's expected it could work in all genetic disorders due to nonsense mutations), the % due to a nonsense mutation can be anything from 5% to 70%. Perhaps someone could find out how many FMO3 mutations are regarded as being due to nonsense mutations.

At the moment the final phase of the muscular dystrophy trial is underway, and now Dr Christodoulou proposes to trial it for trimethylaminuria too, as other researchers are free to do so as well. It's remarkable that a drug may soon be available that can improve enzyme function in genetic cases.

More posts will follow about PCT124. in the meantime, here are some links about it:

PTC therapeutics webpage for PTC124/Ataluren
PTC124/Ataluren FAQs
PTC124 clinical trials article: Simple-powder to beat 400+ genetic disorders : latest on PTC124 trials 2007 interview with PTC therapeutics President

In Spanish


Post a Comment